Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jelena Kunovac

Psychiatry Las Vegas, NV Medical Doctor

NPI 1851402259 CMS profile 38079

3012 W Charleston Blvd Ste 100, Las Vegas, NV 89102

Open in the dashboard

General payments

$1,240,962

1,123 records reported · program years 2019–2025

Research payments

$5,201

Paid to them · 26 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$11,150,323 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jelena Kunovac of Las Vegas, NV is reported in the CMS Open Payments database as having received $1,240,962 across 1,123 general payments and $5,201 in research payments paid to them. Separately, studies naming them as principal investigator received $11,150,323 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $222,759 205
2025 Research $224 1
2024 General $360,068 333
2023 General $215,061 175
2022 General $79,085 58
2021 General $95,840 71
2020 General $44,277 43
2019 General $223,872 238
2019 Research $4,977 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jelena Kunovac
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Jelena Kunovac were reported at $222,759. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Jelena Kunovac Psychiatry median Middle half National median
2019 $223,872 $184 $59–$605 $163
2020 $44,277 $119 $36–$372 $114
2021 $95,840 $143 $43–$576 $132
2022 $79,085 $153 $50–$590 $149
2023 $215,061 $170 $56–$651 $160
2024 $360,068 $179 $57–$673 $164
2025 $222,759 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Otsuka America Pharmaceutical, Inc. $313,104 294 payments
  2. Alkermes, Inc. $300,531 286 payments
  3. ITI, Inc. $234,472 203 payments
  4. E.R. Squibb & Sons, L.L.C. $123,758 107 payments
  5. Axsome Therapeutics, Inc. $95,938 77 payments
  6. Sunovion Pharmaceuticals Inc. $73,830 69 payments
  7. Vanda Pharmaceuticals Inc. $60,524 47 payments
  8. Janssen Pharmaceuticals, Inc $20,515 27 payments
  9. Indivior Inc. $11,185 3 payments
  10. LivaNova USA, Inc. $6,276 3 payments
  11. Other $829 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $828,658 275 payments
  2. Consulting Fee $225,372 85 payments
  3. Travel and Lodging $131,399 436 payments
  4. Honoraria $35,463 15 payments
  5. Food and Beverage $20,070 312 payments
Products named General payments · program years 2019–2025
  1. CAPLYTA $188,090 152 payments
  2. ARISTADA Cns $178,697 164 payments
  3. ARISTADA Cns $178,697 164 payments
  4. ARISTADA Cns $178,697 164 payments
  5. ARISTADA Cns $178,697 164 payments
  6. ARISTADA INITIO $166,884 156 payments
  7. ABILIFY MAINTENA $156,836 148 payments
  8. REXULTI $149,966 150 payments
  9. LYBALVI Cns $130,445 119 payments
  10. LYBALVI Cns $118,632 111 payments
  11. Other $662,690 606 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $2,329 12 payments
  2. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,353 6 payments
  3. Corcept Therapeutics $1,295 7 payments
  4. Eli Lilly and Company $224 1 payment

Records

1,149 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record